Here Are 6 Things You Should Do At Night To Be Happier The Next Morning, According To Experts
You might be surprised at how a few small tweaks to your nighttime habits can make a considerable difference in your happiness come morning.
We asked experts to share what evening practices will have the most positive effect on your mood the following day. Here's what we learned:
Take an evening walk.
Related:
Maybe it's a post-dinner stroll around the block or one last potty walk with your dog before you turn in for the night. But just a few minutes of gentle movement outdoors can reduce blood sugar levels after a meal and help you wind down.
'I go for a walk every evening, which allows me to process the day's information as my blood flow increases to my brain,' U.K. psychologist and well-being specialist Lee Chambers told HuffPost. 'This mental tidying up gives my busy mind a level of peace, meaning I go to bed with a quiet environment and a quiet internal dialogue.'
If you're going to be walking outside when it's dark, be sure to take some basic safety precautions: wear reflective gear or bright-colored clothes, choose a well-lit and familiar route, ask someone else to tag along or bring your phone just in case you need it (but avoid texting, putting in your headphones or other distractions).
Put your phone down, ideally in another room.
You've no doubt noticed that a good night's sleep has a significant effect on your mental state the next morning — and there's 'tons of evidence' supporting that, said Laurie Santos, a Yale University psychology professor and host of The Happiness Lab podcast.
To get better-quality rest, focus on improving your 'sleep hygiene,' which refers to the lifestyle habits and environmental factors that affect our sleep. And how we use our devices at night is a big part of that.
'Turn off your screens about 30 minutes before bed, and consider keeping your devices away from your bed so you're not tempted to check them out at night,' Santos told HuffPost. 'I also recommend getting one of those old-school alarm clocks that don't talk to social media or your email.'
We live in a hyperstimulating world that can put our senses on overdrive, Chambers said. Avoiding screens is one way to remedy that, but there are other things we can do to soothe our senses.
'Consider stacking sensory wind-down rituals, including relaxing scents, calming sounds and soothing warm drinks, allowing our senses to disconnect and connect back with more strength the following morning,' he said.
Take a warm bath (or shower).
Related:
Justine Grosso, a mind-body psychologist licensed in New York and North Carolina, is a proponent of an evening bath for its physical and mental health benefits, she told HuffPost.
'Totally immersing yourself in water, as opposed to showering, has been shown to lift mood in people with depression, improve sleep for people with insomnia and have positive effects on the cardiovascular system,' she explained.
That being said, if you don't have a tub or if baths just aren't your thing, a pre-bed shower ritual has benefits, too. As sleep adviser Robert Oexman previously told HuffPost, 'showering at night can enhance sleep by augmenting the decrease in core body temperature that is necessary to initiate sleep and maintain proper sleep at night.'
Do a body scan.
Related:
According to Cortland Dahl, a research scientist at the University of Wisconsin-Madison's Center for Healthy Minds, a mindful body scan is a powerful way to ease chronic stress and mental rumination. You can do this simple mindfulness exercise while lying in bed.
'Bring attention to each part of your body, starting with your head and moving slowly down until you reach your toes,' he told HuffPost. 'Pay attention to the sensations you notice in your body with a sense of warmth and non-judgmental curiosity. This activates the brain network critical for self-regulation and inner balance. It's also a great way to de-stress and let go of all the tension that builds up in our busy lives.'
Grosso also suggests practices like yoga nidra (a meditative technique in which you 'cycle your awareness around your body,' she said) or gentle stretching. Either will activate your parasympathetic nervous system — the one responsible for the body's 'rest and digest' response.
This method 'helps you feel more calm and drift off to a night of restorative sleep,' she said. 'Over time these practices can help your body more reliably and quickly return to a sense of ease and emotional regulation after a stressful event.'
Reflect on the day.
Related:
Many of us are more likely to fret about all the things we haven't checked off our to-do list on a given day than we are to stop and appreciate the progress we made.
'Whether written or reflected upon, note the steps taken towards a goal, the challenges overcome or tasks completed, no matter how small,' Chambers said. 'And that feeling of progression will create the groundwork for some forward momentum on the following day.'
Dahl also called self-reflection 'a great practice to end a busy day.' He suggests taking a moment to think about what you learned and how you grew that day.
'See if you can reframe stressful events as opportunities for self-discovery or to align with your most cherished values or guiding principles,' he said. 'This simple practice strengthens our capacity for insight and can help us to approach the next day with an open mind that is ready to learn.'
End your day with gratitude.
Before you go to sleep, write down three to five things you're thankful for. Santos pointed to the research of psychologist Robert Emmons, a professor at the University of California, Davis. He and his colleagues 'found that the simple act of listing your blessings in life can lead to significant improvements in your well-being,' she said. 'So make your night-time gratitude list a daily habit.'
Dahl also recommends closing out the day with a short gratitude practice.
'If you spend a few minutes reflecting on people you appreciate and things you're grateful for as part of your bedtime routine, you'll naturally feel less stressed and more connected as you drift off to sleep,' he said. This article originally appeared on HuffPost.
Also in Goodful:
Also in Goodful:
Also in Goodful: Solve the daily Crossword

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Swinney praises Olympic champion Hoy's cancer work after Bute House meeting
Scottish First Minister John Swinney has praised the work done by Sir Chris Hoy to raise awareness of prostate cancer following a meeting at Bute House. The champion cyclist, along with his wife Lady Sarra Hoy, charities and clinicians, met with the First Minister and Health Secretary to discuss how best to tackle prostate cancer on Friday. Sir Chris announced his terminal diagnosis last year and has since urged governments to change their guidelines on the condition, pushing for GPs to contact those in at-risk groups to get tested. Speaking after the meeting, the First Minister said: 'I am extremely grateful to Sir Chris Hoy, Lady Sarra Hoy and all those who shared their valuable insights about how we can work together to better raise awareness and understanding of prostate cancer in Scotland. 'Since the news of his diagnosis last year, Sir Chris has shown tremendous leadership and courage in his campaigning. 'It is a deeply personal issue, but his commitment to helping others is remarkably brave and deservedly recognised. 'We know that the earlier cancer is diagnosed the easier it is to treat, and even cure, which is why the efforts of Sir Chris and others to raise awareness are so valuable. 'I join with a great many others in offering my very best wishes to the Hoy family, and to all families facing the challenges of cancer.' The Olympic champion reiterated his calls for men to get tested if they are worried. 'I welcomed the opportunity to meet with the First Minister, the Health Secretary, doctors and charity leaders so we could talk about our shared commitment to raising awareness and understanding of prostate cancer,' he said. 'I would particularly like to thank the other guests who joined me in talking about their personal experiences. 'Knowing some of the common symptoms of prostate cancer can save lives. These include needing to urinate more often than normal, difficulty urinating or the appearance of blood when you do. 'It is especially important for black men and those who have a family history of prostate cancer to familiarise themselves with the symptoms, but I would encourage anyone with concerns to contact their GP practice for advice as soon as they can.' Since his diagnosis, Sir Chris has focused on raising awareness of prostate cancer and is due to host a major fundraising cycling event in Glasgow in September. Laura Kerby, chief executive officer of Prostate Cancer UK, said the charity was 'delighted to be working with Sir Chris Hoy and the Scottish Government'. She added: 'In the months after Sir Chris shared his story, we saw a huge increase in men using our online risk checker and the number of men in Scotland starting treatment for prostate cancer reached an all-time high. 'We're so grateful for the lifesaving impact he's making and continues to make with events like his upcoming Tour De Four cycling challenge. 'But, today, men in Scotland are still more likely to get a late prostate cancer diagnosis than anywhere else in the UK, so it's incredibly important that we do not take our feet off the pedals. 'We're grateful to the Scottish Government and First Minister John Swinney for assembling such a talented group of experts and leaders in this space today to continue the vital work to change this unacceptable situation.' Alison Wright, chief executive officer of Prostate Scotland, said the meeting was an 'important first conversation'. 'We hope it leads to ongoing collaboration and concrete steps to close detection gaps, so no man at risk is left behind,' she said. 'Far too many men – especially those with a family history, black African or Caribbean heritage, or inherited genetic mutations – are diagnosed late because testing was only prompted by symptoms. 'We advise that clear prompts for GPs be introduced to consider PSA testing based on risk factors alone, not just symptoms. Acting early will save lives.'
Yahoo
an hour ago
- Yahoo
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization Novel, oral candidate with first-in-class potential progresses successfully through Lilly's Phase 1 clinical trial in healthy volunteers Sitryx reintegrates SYX-1042 into portfolio of novel small molecule candidates targeting major autoimmune indications with high unmet need Oxford, UK – 8 August 2025 – Sitryx Therapeutics ('the Company'), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces that the Company has regained the rights to its itaconate mimetic, SYX-1042, for the treatment of chronic autoimmune and inflammatory diseases, from Eli Lilly & Company (Lilly), due to strategic considerations and reprioritization of Lilly's pain and inflammation portfolio. In 2024 Lilly commenced a Phase 1 first-in-human study of SYX-1042, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases, following a research collaboration between the two companies. That study has completed successfully. With the return to Sitryx of SYX-1042, its phase 2-ready data package and associated API, Sitryx is assessing how best to prioritize SYX-1042 for continued in-house development or potential further partnering. Iain Kilty, Chief Executive Officer of Sitryx, commented: 'Through our partner Lilly's investment in the clinical development of SYX-1042, this program has progressed significantly, delivering positive first-in-human data. We will be reviewing this clinical data alongside the robust preclinical data package to determine the optimal path forward. We thank Lilly for this collaboration and the advances we made together, progressing important research into a first-in-class candidate which we believe holds exciting potential in multiple chronic autoimmune and inflammatory diseases.' -Ends- For more information about Sitryx please contact: ICR HealthcareMary-Jane Elliott, David Daley +44 (0)20 3709 5700Sitryx@ About SitryxSitryx is a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease. The Company has a broad pipeline of novel small molecule candidates targeting major autoimmune indications with high unmet need. Its lead candidate, SYX-5219, is a potentially first-in-class PKM2 modulator in development for atopic dermatitis as a once-daily oral therapy with future development potential across multiple autoimmune diseases. Established in 2018 with seed funding from SV Health Investors, Sitryx has raised $85 million to date from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK. Sitryx is headquartered in Oxford, UK. For more information, please visit in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
an hour ago
- Medscape
Transplanted Islet Cells Survive Without Immune Suppression
For the first time, researchers have transplanted gene-edited donor islet cells that secrete insulin in a person with type 1 diabetes (T1D) without the use of immunosuppression. Twelve-week results from the phase 1, single-participant study were published online on August 4, 2025, as a Brief Report in The New England Journal of Medicine . Six-month data were presented on June 23, 2025, at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago and announced at the time in a press release from Sana Biotechnology. The study subject, a 42-year-old man with a 37-year history of T1D, has shown no immune response to the gene-edited cells and has maintained ongoing significant circulating C-peptide levels, a measure of insulin secretion, in contrast to zero at baseline. MRI at 12 weeks confirmed persistence of the grafted hypoimmune islets. At 6 months, increased C-peptide levels in response to a mixed-meal tolerance test were seen. He still requires insulin treatment, but that was expected because the protocol for this early safety study involved delivery of only 7% of the number of cells that would be curative, lead author Per-Ola Carlsson, MD, PhD, senior physician and professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital, Uppsala, Sweden, told Medscape Medical News . 'Excited,' but 'Many Hurdles to Overcome' Currently, transplantation for treatment of T1D — whether of whole pancreas, cadaveric donor islets, or experimental stem cell-derived islets — is reserved for individuals with frequent severe hypoglycemia or those who are already undergoing another transplant, such as a kidney. In most people with managed T1D, the adverse health risks for immune suppression are viewed as outweighing the benefits of a transplant. In T1D, transplantation provokes two immune system attacks: one against any foreign body, which is common to all organ transplants (allogeneic), and a second to the beta cell-specific autoantibodies that caused the condition in the first place. Thus far, it appears that this novel gene-editing approach overcomes both allogeneic and autoimmune rejection. If upcoming trials using stem cell-derived islets that can be produced in unlimited quantities validate these results, this approach could essentially represent a cure for many people T1D, Carlsson said. 'I have never been so excited in my life. I've been working with the science since the 1990s, and this is the one project that has been so positive and so convincing. I'm really happy to work with it, and since I'm a clinician, it's magic to be able to do something that could turn into a reality for these patients,' he told Medscape Medical News . However, he cautioned, 'This is one subject…we believe it is applicable to all subjects with type 1 diabetes. But of course, there may be subgroups that it does not work for.' Moreover, he noted, 'It will take time before it reaches clinical reality.' Experts in the field contacted by Medscape Medical News expressed cautious optimism. Mark A. Atkinson, PhD, the ADA Eminent Scholar for Diabetes Research and professor in the Department of Pathology at the University of Florida, Gainesville, Florida, said, 'I am very enthusiastic about this study. I think this is a baby step, with the potential for moving forward a full leap. Time will tell. At a minimum, this shows that genetic modification of a stem cell source may prove valuable as a future therapeutic for type 1 diabetes.' However, Atkinson noted that because the treatment is likely to be expensive, 'the cost versus benefit ratio of using such a therapy across the spectrum of type 1 diabetes needs further exploration.' Islet cell transplantation pioneer A.M. James Shapiro, MD, Canada Research Chair in Transplantation Surgery and Regenerative Medicine at the University of Alberta, Edmonton, Alberta, told Medscape Medical News 'This is indeed an exciting development in that human insulin-producing islet cells continued to secrete, albeit small amounts of insulin in the absence of immune suppression. Ongoing research will determine whether this approach can be effectively scaled up and engraftment improved.' David M. Harlan, MD, director of the Breakthrough T1D Barbara D. Cammett Center of Excellence in New England and co-director of the University of Massachusetts (UMass) Diabetes Center of Excellence, Worcester, Massachusetts, said, 'I believe that the genetic modifications of stem cell-derived islets and/or a druggable target within a stem cell-derived islet is likely to represent a practical cure for type 1 diabetes in the next decade or so. I'm excited by this step, but I still see many hurdles to overcome.' Hypoimmune Islets: Breakthrough or Baby Step? Some of the 'hurdles' cited by Harlan, who is also the William and Doris Krupp Professor of Medicine at UMass, relate to the gene-editing procedure itself and to some of the study methodology. The islets, from a deceased donor with the same blood type as the recipient, were first dissociated into single cells, and the genes encoding human leukocyte antigen (HLA) class I and class II were inactivated using clustered regularly interspaced short palindromic repeat. The cells were reclustered, again dissociated, and transduced with a lentiviral vector containing CD47 complementary DNA. Knocking out HLA class I and II is necessary to protect against adaptive T-cell rejection, while overexpression of CD47 inhibits innate killing via macrophages and natural killer cells, Carlsson explained. According to Harlan, even without HLA class I and II, there would still be other cell surface molecules that would be expected to provoke an antibody response. 'I just don't understand why they don't see any donor-specific antibodies against the gene-modified islets. That doesn't make sense to me. Maybe such antibodies would be benign, but I would still expect them to be picked up.' Carlsson countered, 'Detection of foreign cells is through HLA. Other antigens…are, even if not encoded from the HLA class I or class II genes, presented to the immune system by the HLA molecules.' Atkinson noted that the autoimmune response could take much longer to occur than the allogeneic, and therefore longer follow-up is needed. Carlsson said that the planned follow-up is 15 years, but prior data suggest that the autoimmunity would occur within 1-2 months, and 'we didn't see any attack at all.' Harlan also noted that the patient's high baseline A1c, 10.9%, was unusual and might have adversely affected the findings. Carlsson said that this was per request of the regulatory bodies because such an individual would 'gain most from the development of a curing therapy considering their high risk of complications.' He added that this requirement 'complicated the study since high glucose stresses the beta cells…we were, however, able to improve his metabolic control post-transplantation.' The gene-edited cells were delivered with 17 separate injections — to allow for sufficient oxygen exposure — into the patient's forearm while he was under general anesthesia. Both Harlan and Atkinson questioned the feasibility of that approach going forward. Carlsson said that the forearm was chosen because it was simpler to monitor for safety, but that in future studies abdominal muscles might be used. Sana Biotechnology will not study this product, UP421, further. Instead, they are moving forward with SC451, a stem cell-derived pancreatic gene-edited islet cell product. The next study is still being planned but will involve multiple patients at more than one clinical site, Carlsson told Medscape Medical News . Atkinson commented, 'Over 50 years ago, individuals with type 1 diabetes were told that a cure was on the way, and it was going to occur through islet cell transplantation and understanding of the autoimmune nature of type 1 diabetes. There were animal models of the disease, and there were new classes of drugs that came out, namely cyclosporine. So, people had hopes that a cure for type 1 diabetes was 3-5 years away. Now, six decades later, we're still struggling with that, but there's promise on the horizon.' Carlsson and Shapiro reported having no disclosures. Atkinson is a consultant for Vertex, Sanofi, Diamyd, Novo Nordisk, and Sernova. Harlan is co-founder and chief scientific officer for Stability Health, LLC; a consultant for CG Scientific, Inc.; and chair of the scientific advisory board for TIXiMED.